The Cell Imaging and Microscopy Shared Resource (CIM) provides cellular imaging technologies and services to enhance the programmatic research objectives of the Winship Cancer Institute (Winship). It is centrally located in Winship and houses state-of-the-art technologies including point scanning confocal, live cell confocal, spectral confocal imaging, epifluorescence microscopy, and image processing and analysis. CIM services have supported numerous Winship programmatic initiatives that include cancer cell biology, biomarker development, cancer nanotechnology, tumor diagnostics, drug delivery, and molecular pharmacology. These interactions have resulted in high Impact publications, team science grants, and inter- and intra-programmatic collaborations. Winship members comprise 88% of total CIM usage, with overall usage increasing from 1533 hours in calendar year 2008 to 4332 hours in 2010. CIM personnel provide consultation on experimental setup, execution, and analysis to ensure optimal image acquisition and data analysis. This includes comprehensive training sessions and dally user assistance to ensure that technologies are properly utilized. Alt user image data are archived nightly onto NAS enterprise level RAID protected servers to provide secure data backup. The CIM is a Winship shared resource, and Winship is responsible for oversight, operations, budget, compliance, user fee collection, and employee relations. The CIM Director makes all day-to-day decisions with input from CIM personnel, users, an internal advisory board, and executive oversight committee. The primary objectives of the CIM over the next two years are to expand small animal fluorescence imaging resources, implement a new assay development service, and continue to expand our IT infrastructure. These new technologies along with existing CIM services will enhance Winship's basic, translational, and clinical initiatives of Winship.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
United States
Zip Code
Danish, Hasan; Ferris, Matthew J; Balagamwala, Ehsan et al. (2018) Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma. Melanoma Res 28:120-125
Barwick, Benjamin G; Scharer, Christopher D; Martinez, Ryan J et al. (2018) B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation. Nat Commun 9:1900
Liu, Fakeng; Liu, Yuan; Liu, Xiuju et al. (2018) Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. Lung Cancer 123:36-43
Kennedy, E M; Powell, D R; Li, Z et al. (2018) Galactic Cosmic Radiation Induces Persistent Epigenome Alterations Relevant to Human Lung Cancer. Sci Rep 8:6709
Xiao, Canhua; Beitler, Jonathan J; Higgins, Kristin A et al. (2018) Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer. Brain Behav Immun 74:291-295
Cassidy, Richard J; Zhang, Xinyan; Switchenko, Jeffrey M et al. (2018) Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer 124:775-784
Jhaveri, Jaymin; Chowdhary, Mudit; Zhang, Xinyan et al. (2018) Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases. J Neurosurg :1-7
Jhaveri, Jaymin; Rayfield, Lael; Liu, Yuan et al. (2018) Impact of intensity modulated radiation therapy on survival in anal cancer. J Gastrointest Oncol 9:618-630
Bilen, Mehmet Asim; Dutcher, Giselle Marie Almeida; Liu, Yuan et al. (2018) Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clin Genitourin Cancer 16:e563-e575
Chowdhary, Mudit; Switchenko, Jeffrey M; Press, Robert H et al. (2018) Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol 139:689-697

Showing the most recent 10 out of 331 publications